← Leaderboards
Clifford Cho
Wm S. Middleton Memorial Veterans Hosp
$1,316,423
Attributed
$1,316,423
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $496.8K · FY2014–25$500K$375K$250K$125K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,316,423 · 1
VA$0 · 1
By mechanism
R01$1,316,423 · 1
I01$0 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Melanoma”
- David Heimbrook · Leidos Biomedical Research, Inc.$206,517,726
- Richard L Schilsky · University Of Chicago$108,377,382
- Larry Arthur$59,113,709
- Charles A Coltman · Southwest Oncology Group$55,198,633
- Robert L Comis · Frontier Sci &Technology Rsch Fdn, Inc$47,956,689
- Meenhard Herlyn · University Of Pennsylvania$46,448,742
Research focus
MelanomaAntigensImmunotherapyTumorNeoplastic CellMalignant NeoplasmsSeriesPre-ClinicalTumor AntigensImmuneImmune SystemImmune ResponseCellsAblationAdoptive ImmunotherapyAntigen PresentationFoundationsIn VivoCd8-Positive T-LymphocytesCytokineCancer CellCancer ImmunotherapyExposure ToInterleukin-15
Grant awards (14)
Harnessing the therapeutic potential of histotripsy focused ultrasound-induced immunogenic cancer cell death$496,811
R01 · FY2025 · CA · contact PI
Harnessing the therapeutic potential of histotripsy focused ultrasound-induced immunogenic cancer cell death$320,452
R01 · FY2024 · CA · contact PI
Harnessing the therapeutic potential of histotripsy focused ultrasound-induced immunogenic cancer cell death$78,847
R01 · FY2024 · CA · contact PI
Harnessing the therapeutic potential of histotripsy focused ultrasound-induced immunogenic cancer cell death$420,313
R01 · FY2023 · CA · contact PI
Re-engineering the tumor draining lymph node to achieve memory T cell-based adoptive immunotherapy$0
I01 · FY2022 · VA · contact PI
Re-engineering the tumor draining lymph node to achieve memory T cell-based adoptive immunotherapy$0
I01 · FY2022 · VA · contact PI
Re-engineering the tumor draining lymph node to achieve memory T cell-based adoptive immunotherapy$0
I01 · FY2021 · VA · contact PI
Re-engineering the tumor draining lymph node to achieve memory T cell-based adoptive immunotherapy$0
I01 · FY2020 · VA · contact PI
Re-engineering the tumor draining lymph node to achieve memory T cell-based adoptive immunotherapy$0
I01 · FY2019 · VA · contact PI
Re-engineering the tumor draining lymph node to achieve memory T cell-based adoptive immunotherapy$0
I01 · FY2018 · VA · contact PI
Preclinical Optimization of Melanoma Adoptive T Cell Immunotherapy$0
I01 · FY2017 · VA · contact PI
Preclinical Optimization of Melanoma Adoptive T Cell Immunotherapy$0
I01 · FY2016 · VA · contact PI
Preclinical Optimization of Melanoma Adoptive T Cell Immunotherapy$0
I01 · FY2015 · VA · contact PI
Preclinical Optimization of Melanoma Adoptive T Cell Immunotherapy$0
I01 · FY2014 · VA · contact PI